Michael R. Hayden

CIK: 0001352908

Transaction Breakdown

Open Market Buys (P)7 (24.1%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (3.4%)

Derivative conversions

Awards (A)7 (24.1%)

Compensation grants

Other (G, F, J, C, D, …)14 (48.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ABCL

AbCellera Biologics Inc.

Director

IONS

IONIS PHARMACEUTICALS INC

Director

ETNB

89bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (29 total)

ABCL
AbCellera Biologics Inc.
Aug 24, 2026
Purchase(P)
Indirect
53.6K shares at avg. $10.64$570K
ABCL
AbCellera Biologics Inc.
Aug 12, 2026
Purchase(P)
Indirect
46.4K shares at avg. $10.37$481K
ABCL
AbCellera Biologics Inc.
Aug 11, 2026
Gift(G)
Indirect
50K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 31, 2026
Purchase(P)
Indirect
5K shares at avg. $51.60$258K
IONS
IONIS PHARMACEUTICALS INC
Jul 30, 2026
Purchase(P)
Indirect
15K shares at avg. $53.38$801K
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2026
Award(A)
Restricted Stock Unit
Direct
2.3K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
5.4K shares-
ABCL
AbCellera Biologics Inc.
Jun 11, 2026
Award(A)
Share option (right to buy)
Direct
111.7K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Tender Offer(U)
Direct
80.9K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Tender Offer(U)
Indirect
104K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Tender Offer(U)
Indirect
61.5K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
22.7K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
7K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
7K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
12.5K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
25K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
27.4K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
45.2K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
56.4K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
27.6K shares-
ETNB
89bio, Inc.
Oct 30, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
2.9K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 15, 2025
Exercise(M)
Direct
4.1K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
11.5K shares-
IONS
IONIS PHARMACEUTICALS INC
Jul 1, 2025
Award(A)
Restricted Stock Unit
Direct
5.2K shares-
ABCL
AbCellera Biologics Inc.
Jun 12, 2025
Award(A)
Share option (right to buy)
Direct
238.9K shares-

		Type	Shares	Price		Ownership
Aug 24, 2026	ABCL AbCellera Biologics Inc.	Purchase(P)	53,613	$10.64	$570,442	Indirect
Aug 12, 2026	ABCL AbCellera Biologics Inc.	Purchase(P)	46,387	$10.37	$481,033	Indirect
Aug 11, 2026	ABCL AbCellera Biologics Inc.	Gift(G)	50,000	-	$0	Indirect
Jul 31, 2026	IONS IONIS PHARMACEUTICALS INC	Purchase(P)	5,000	$51.60	$258,000	Indirect
Jul 30, 2026	IONS IONIS PHARMACEUTICALS INC	Purchase(P)	15,000	$53.38	$800,700	Indirect
Jul 1, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	2,301	-	-	Direct
Jul 1, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Non-Qualified Stock Option (right to buy)	5,369	-	-	Direct
Jun 11, 2026	ABCL AbCellera Biologics Inc.	Award(A) Share option (right to buy)	111,701	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Tender Offer(U)	80,904	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Tender Offer(U)	103,978	-	-	Indirect
Oct 30, 2025	ETNB 89bio, Inc.	Tender Offer(U)	61,538	-	-	Indirect
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	22,730	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	7,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	7,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	12,500	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	25,000	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	27,400	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	45,150	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	56,400	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	27,647	-	-	Direct
Oct 30, 2025	ETNB 89bio, Inc.	Disposition(D) Stock Option (Right to Buy)	2,933	-	-	Direct
Jul 15, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	4,079	-	-	Direct
Jul 1, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Non-Qualified Stock Option (right to buy)	11,518	-	-	Direct
Jul 1, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	5,220	-	-	Direct
Jun 12, 2025	ABCL AbCellera Biologics Inc.	Award(A) Share option (right to buy)	238,864	-	-	Direct

1-25 of 29 transactions

About Hayden Michael R

Hayden Michael R (SEC CIK 0001352908) files insider reports with the SEC as Director of AbCellera Biologics Inc. (ABCL), Director of IONIS PHARMACEUTICALS INC (IONS) and Director of 89bio, Inc. (ETNB).

Signal8 holds 13 ownership filings by Hayden Michael R, all Form 4s, filed between Dec 26, 2024 and Aug 24, 2026. Those filings report 29 transactions, from Dec 23, 2024 to Aug 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hayden Michael R's filings is in VANCOUVER.

Recent filings by Hayden Michael R

Aug 24, 2026: Open-market purchase of ABCL shares (Form 4, code P).
Aug 12, 2026: Open-market purchase of ABCL shares (Form 4, code P).
Aug 11, 2026: Gift of ABCL shares (Form 4, code G).
Jul 31, 2026: Open-market purchase of IONS shares (Form 4, code P).
Jul 30, 2026: Open-market purchase of IONS shares (Form 4, code P).

Other insiders filing for AbCellera Biologics Inc. (ABCL)

Montalbano John S., Director
Booth Andrew, Chief Financial Officer
Seely Lynn, Director
Sandor Victor, Director
Quake Stephen, Director
Thermopylae Holdings Ltd., 10% Owner

How to read Form 4 transaction codes